Brixadi™ (buprenorphine) – New drug approval
May 23, 2023 - Braeburn announced the FDA approval of Brixadi (buprenorphine), for the treatment of moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
Top